Zhongtai Securities released a research report on April 22 stating that it will maintain the purchase rating of Jiete Biotech (688026.SH). The main reasons for the rating include: 1) the company released its 2023 annual report, and the company achieved revenue in 2023; 2) factors such as reduced revenue and increased depreciation investment affected short-term profit margins; 3) performance declined due to adverse effects such as geopolitics, inventory digestion, and production capacity clearance, which is expected to usher in healthy growth in 2024; 4) the gradual implementation of intelligent manufacturing projects and the accelerated expansion of domestic and foreign markets. (Mainichi Keizai Shimbun)